{"symbol":"REGN","fiscalQuarter":"Q4-2025","reportDate":"2026-01-30","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2025","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.07%","keyNumbers":[{"metric":"EPS","actual":"$11.44","expected":"N/A","surprise":"+38.18%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key products.","They emphasized ongoing investment in R&D to drive future growth."],"summary":"Overall, management expressed confidence in their product pipeline and the company's ability to navigate market challenges. However, they acknowledged the competitive landscape."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 1.07% in reaction to the lack of revenue data and guidance. Investors may be cautious due to the absence of future projections, despite the positive EPS surprise.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2025 earnings: EPS beat expectations. Stock down 1.07%. Full breakdown."}}